首页> 外文期刊>Osteoarthritis and cartilage >Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis.
【24h】

Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis.

机译:营养补充剂二甲基亚砜(DMSO)和甲基磺酰甲烷(MSM)在骨关节炎治疗中的系统评价。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Conventional treatment of osteoarthritis (OA) with non-steroidal anti-inflammatory drugs is associated with serious gastrointestinal side effects and in view of the recent withdrawal of some cyclo-oxygenase-2 inhibitors, identifying safer alternative treatment options is needed. The objective of this systematic review is to evaluate the existing evidence from randomised controlled trials of two chemically related nutritional supplements, dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of OA to determine their efficacy and safety profile. METHODS: The electronic databases [Cochrane Library, Medline, Embase, Amed, Cinahl and NeLH (1950 to November 2007)] were searched. The search strategy combined terms: osteoarthritis, degenerative joint disorder, dimethyl sulfoxide, DMSO, methylsulfonylmethane, MSM, clinical trial; double-blind, single blind, RCT, placebo, randomized, comparative study, evaluation study, control. Inclusion and exclusion criteria were applied. Data were extracted and quality was assessed using the JADAD scale. RESULTS: Six studies were included [evaluating a total of 681 patients with OA of the knee for DMSO (N=297 on active treatment); 168 patients for MSM (N=52 on active treatment)]. Two of the four DMSO trials, and both MSM trials reported significant improvement in pain outcomes in the treatment group compared to comparator treatments, however, methodological issues and concerns over optimal dosage and treatment period, were highlighted. CONCLUSION: No definitive conclusion can currently be drawn for either supplement. The findings from all the DMSO studies need to be viewed with caution because of poor methodology including; possible unblinding, and questionable treatment duration and dose. The data from the more rigorous MSM trials provide positive but not definitive evidence that MSM is superior to placebo in the treatment of mild to moderate OA of the knee. Further studies are now required to identify both the optimum dosage and longer-term safety of MSM and DMSO, and definitive efficacy trials.
机译:目的:用非甾体类抗炎药常规治疗骨关节炎(OA)与严重的胃肠道副作用有关,并且鉴于最近撤消了一些环氧合酶-2抑制剂,需要确定更安全的替代治疗方案。该系统评价的目的是评估两种化学相关的营养补品(二甲基亚砜(DMSO)和甲基磺酰甲烷(MSM))在治疗OA中的随机对照试验中的现有证据,以确定其疗效和安全性。方法:搜索电子数据库[Cochrane图书馆,Medline,Embase,Amed,Cinahl和NeLH(1950年至2007年11月)。搜索策略结合了以下术语:骨关节炎,退行性关节疾病,二甲基亚砜,DMSO,甲基磺酰甲烷,MSM,临床试验;双盲,单盲,RCT,安慰剂,随机,比较研究,评估研究,对照。应用纳入和排除标准。提取数据并使用JADAD量表评估质量。结果:纳入了六项研究[评估了共681例膝关节骨关节炎的DMSO患者(积极治疗时N = 297); 168例MSM患者(积极治疗时N = 52)]。四个DMSO试验中的两个以及两个MSM试验均报告说,与对照组相比,治疗组的疼痛结局有了明显改善,但是,方法学问题以及对最佳剂量和治疗时间的关注都得到了强调。结论:目前尚不能对任何一种补充剂得出明确的结论。由于方法不完善,所有DMSO研究的发现都应谨慎对待。可能导致失明,并且治疗时间和剂量有问题。来自更严格的MSM试验的数据提供了积极但不确定的证据,表明MSM在治疗膝部轻度至中度OA方面优于安慰剂。现在需要进一步的研究来确定MSM和DMSO的最佳剂量和长期安全性,以及确定的功效试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号